20 Years ProBioGen
News Sep 10, 2014
On the occasion of its 20th anniversary, ProBioGen AG has announced to invest 20€ million and to double its workforce. CEO Dr. Wieland Wolf welcomed scientific, business and political guests in a ceremony in Berlin on September 4, 2014.
On behalf of pharmaceutical and biotech companies ProBioGen is developing novel biotechnological processes for the production of biopharmaceutical drug substances to treat serious diseases. The service spectrum ranges from cell line and process development up to GMP contract manufacturing.
In addition, the Berlin scientists develop innovative technologies to improve biotechnologically active substances and by virtue of their recognized scientific excellence created an extensive portfolio of proprietary rights for optimized biopharmaceutical manufacturing.
In recent times, licenses were granted to several global pharmaceutical companies, including Boehringer Ingelheim and Novartis. Beyond that, ProBioGen will further exploit its internal potential for the development of production cell lines, process engineering and GMP manufacturing of biopharmaceuticals.
"Together with our parent company, we will continue to expand and invest in Berlin," comments Dr. Wieland Wolf. "With an investment of around 20 million euros, we will strengthen our market position, add two additional disposable 1000L bioreactors and, within the next two years, will double our staff from currently 75 highly skilled and dedicated employees" says the CEO about ProBioGen's further growth.
Dr. Wafik Bardissi, chairman of the board, announced on behalf of Minapharm Pharmaceuticals to continually invest in its two biotech sites, Berlin and Cairo, and in the development of new drugs, using synergies from both sites. The primary objective is to deliver innovative and affordable medications for patients in Egypt and other low-income countries.
As part of the ceremony the ProBioGen Innovation Prize was granted by CSO Dr. Volker Sandig to molecular biologist Thomas Rose. Through his scientific research to increase cellular productivity ProBioGen now has available "super producers by stimulating the cellular secretion apparatus".
Through a unique molecular biological intervention with the cell metabolism he was able to tremendously increase the cellular production capacity and thus achieve a competitive advantage for ProBioGen.
Horizon Enters into Partnership with Pirbright Institute to Improve Vaccine YieldsNews
Extends Horizon’s biomanufacturing capabilities into vaccine manufacture. Research supported by a grant from the Canadian International Development Research Centre, funded by the Bill and Melinda Gates foundation.READ MORE
PhoreMost and Plexxikon Collaborate to Identify Novel Drug TargetsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo.READ MORE
Lonza Opens World’s Largest Dedicated Cell-and-Gene-Therapy Manufacturing Facility in TexasNews
First-of-its-kind, state-of-the-art manufacturing facility with capacity to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases.READ MORE
Comments | 0 ADD COMMENT
Asia Pacific Congress on Probiotics, Prebiotics and Nutrition
Oct 15 - Oct 16, 2018
15th Symposium on the Practical Applications of Mass Spectrometry in the Biotechnology Industry
Sep 09 - Sep 12, 2018